专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5441972A Pharmaceutical use of pyridoxal derivative 失效
标题翻译：药物使用吡哆醛衍生物
公开(公告)号：US5441972A
公开(公告)日：1995-08-15
申请号：US222596
申请日：1994-04-04
申请人： Kazumi Ogata , Shunji Sogo , Eri Inoue
发明人： Kazumi Ogata , Shunji Sogo , Eri Inoue
IPC分类号： A61K31/44
CPC分类号： A61K31/44 , Y10S514/912
摘要： A novel use of the compound of the formula ##STR1## wherein R.sub.1 is hydrogen atom or lower alkyl and R.sub.2 is hydrogen atom or phosphoric acid group, or a pharmacologically acceptable salt thereof for preventing and treating cataract. The compounds of the formula (I) and pharmacologically acceptable salts thereof of the present invention inhibit initial changes in the lens, such as vacuolation and trochoidal change, and almost completely inhibit a decrease in the amounts of reduced glutathione and cysteine in the lens, so that they are advantageously used for the prevention of the onset and progress of cataract.
摘要翻译：其中R 1为氢原子或低级烷基且R 2为氢原子或磷酸基团的式（I）化合物或其药理学上可接受的盐用于预防和治疗白内障的新用途。本发明的式（I）化合物及其药理学上可接受的盐抑制透镜的初始变化，例如空泡化和摆线变化，并且几乎完全抑制透镜中还原型谷胱甘肽和半胱氨酸的量的降低，因此它们有利地用于预防白内障的发作和进展。

2. 发明授权

US5871739A Pharmaceutical composition 失效
标题翻译：药物组成
公开(公告)号：US5871739A
公开(公告)日：1999-02-16
申请号：US729152
申请日：1996-10-11
申请人： Eri Inoue
发明人： Eri Inoue
IPC分类号： A61K38/00 , C07K14/47 , C07K16/18 , A61K39/00
CPC分类号： C07K16/18 , C07K14/47 , A61K38/00
摘要： A pharmaceutical composition comprising, as an active ingredient, a lens antigen which induces a lens cell damaging immune response or a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response. The pharmaceutical composition of the present invention containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen shows markedly superior inhibitory effects on the increase of an anti-lens protein antibody titer. Therefore, it most probably treats or prevents cataract effectively, and delays onset of cataract. Thus, the composition is extremely useful for cataract patients and reserve patients of cataract.
摘要翻译：一种药物组合物，其包含作为活性成分的诱发晶状体细胞损伤免疫应答的晶状体抗原或能够表达镜片抗原的微生物，其诱导晶状体细胞损伤免疫应答。含有透镜抗原或能够表达所述抗原的微生物作为活性成分的本发明的药物组合物对抗晶状体蛋白抗体滴度的增加显示出显着优异的抑制作用。因此，它最有可能有效治疗或预防白内障，并延缓白内障发作。因此，该组合物对白内障患者和白内障预留患者非常有用。

3. 发明申请

US20060247293A1 Agent for therapeutic treatment of optic nerve diseases and the like 失效
公开(公告)号：US20060247293A1
公开(公告)日：2006-11-02
申请号：US11477854
申请日：2006-06-30
申请人： Tomiya Mano , Shunji Sogou , Eri Inoue
发明人： Tomiya Mano , Shunji Sogou , Eri Inoue
IPC分类号： A61K31/4152
CPC分类号： A61K31/00 , A61K31/4152
摘要： The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.

4. 发明申请

US20050004041A1 Novel peptide having angiotensin convertase inibitory effect 有权
标题翻译：新型肽具有血管紧张素转化酶的内在作用
公开(公告)号：US20050004041A1
公开(公告)日：2005-01-06
申请号：US10496200
申请日：2002-11-21
申请人： Yoshitaka Tamura , Hiroshi Miyakawa , Akio Yamada , Hitoshi Saito , Yasushi Kawaguchi , Hiroshi Ochi , Tomoko Ide , Eri Inoue
发明人： Yoshitaka Tamura , Hiroshi Miyakawa , Akio Yamada , Hitoshi Saito , Yasushi Kawaguchi , Hiroshi Ochi , Tomoko Ide , Eri Inoue
IPC分类号： A61K38/00 , A61P9/00 , A61P9/12 , A61P43/00 , C07K5/083 , C07K14/47 , C07K5/06 , A61K38/05
CPC分类号： C07K14/4732 , A61K38/00 , C07K5/081
摘要： A peptide Met-Lys-Pro, which is obtained by chemical synthesis ot hydrolysis of casein, is used as the active ingredient of angiotensin converting enzyme inhibitors or hypotensive drugs.
摘要翻译：用酪蛋白水解化学合成获得的肽Met-Lys-Pro作为血管紧张素转换酶抑制剂或降血压药物的有效成分。

5. 发明授权

US07638516B2 Agent for therapeutic treatment of optic nerve diseases and the like 失效
标题翻译：用于治疗视神经疾病的药剂等
公开(公告)号：US07638516B2
公开(公告)日：2009-12-29
申请号：US11477854
申请日：2006-06-30
申请人： Tomiya Mano , Shunji Sogou , Eri Inoue
发明人： Tomiya Mano , Shunji Sogou , Eri Inoue
IPC分类号： A01N43/58
CPC分类号： A61K31/00 , A61K31/4152
摘要： The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.
摘要翻译：用于本发明治疗和/或预防治疗的药物对由视网膜短暂性视网膜缺血引起的视网膜变性具有抑制作用，其通过抑制视网膜缺血眼视网膜变性的效果的结果来验证。因此，本发明的药物对视神经等疾病具有治疗和/或预防效果。

6. 发明授权

US07022676B2 Peptide having angiotensin converting enzyme inhibitory effect 有权
标题翻译：肽具有血管紧张素转换酶的抑制作用
公开(公告)号：US07022676B2
公开(公告)日：2006-04-04
申请号：US10496200
申请日：2002-11-21
申请人： Yoshitaka Tamura , Hiroshi Miyakawa , Akio Yamada , Hitoshi Saito , Yasushi Kawaguchi , Hiroshi Ochi , Tomoko Ide , Eri Inoue
发明人： Yoshitaka Tamura , Hiroshi Miyakawa , Akio Yamada , Hitoshi Saito , Yasushi Kawaguchi , Hiroshi Ochi , Tomoko Ide , Eri Inoue
IPC分类号： A61K38/00
CPC分类号： C07K14/4732 , A61K38/00 , C07K5/081
摘要： A peptide Met-Lys-Pro, which is obtained by chemical synthesis ot hydrolysis of casein, is used as the active ingredient of angiotensin converting enzyme inhibitors or hypotensive drugs.
摘要翻译：用酪蛋白水解化学合成获得的肽Met-Lys-Pro作为血管紧张素转换酶抑制剂或降血压药物的有效成分。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式